Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Cervical Cancer, December 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 113 articles:
HTML format


 

Single Articles

  1. MENG Y, Li Q, Li L, Ma R, et al
    The long non-coding RNA CRNDE promotes cervical cancer cell growth and metastasis.
    Biol Chem. 2017;399:93-100.
    Abstract    

    Abstract available

  2. ZHANG W, Liu K, Ye B, Liang W, et al
    Pretreatment C-reactive protein/albumin ratio is associated with poor survival in patients with stage IB-IIA cervical cancer.
    Cancer Med. 2017 Nov 28. doi: 10.1002/cam4.1270.
    Abstract    

    Abstract available

  3. MENG J, Zhu L, Zhu L, Xie L, et al
    Whole-lesion ADC histogram and texture analysis in predicting recurrence of cervical cancer treated with CCRT.
    Oncotarget. 2017;8:92442-92453.
    Abstract    

    Abstract available

  4. ZHOU Z, Liu X, Hu K, Zhang F, et al
    The clinical value of PET and PET/CT in the diagnosis and management of suspected cervical cancer recurrence.
    Nucl Med Commun. 2017 Nov 20. doi: 10.1097/MNM.0000000000000775.
    Abstract    

    Abstract available

  5. ZHANG X, Yan Z, Shi L, Yang H, et al
    [Association of HSPA1A gene single nucleotide polymorphisms with the development of cervical cancer among ethnic Han Chinese from Yunnan].
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2017;34:909-914.
    Abstract    

    Abstract available

  6. ROIK EE, Nieboer E, Kharkova OA, Grjibovski AM, et al
    Do Cervical Cancer Patients Diagnosed with Opportunistic Screening Live Longer? An Arkhangelsk Cancer Registry Study.
    Int J Environ Res Public Health. 2017;14.
    Abstract    

    Abstract available

  7. KUSADA T, Toita T, Ariga T, Maemoto H, et al
    Computed tomography-based image-guided brachytherapy for cervical cancer: correlations between dose-volume parameters and clinical outcomes.
    J Radiat Res. 2017 Nov 23:1-10. doi: 10.1093.
    Abstract    

    Abstract available

  8. PEDERSEN K, Burger EA, Campbell S, Nygard M, et al
    Advancing the evaluation of cervical cancer screening: development and application of a longitudinal adherence metric.
    Eur J Public Health. 2017;27:1089-1094.
    Abstract    

    Abstract available

  9. MATSUO K, Shimada M, Saito T, Takehara K, et al
    Risk stratification models for para-aortic lymph node metastasis and recurrence in stage IB-IIB cervical cancer.
    J Gynecol Oncol. 2018;29:e11.
    Abstract    

    Abstract available

  10. MATSUO K, Grubbs BH, Mikami M
    Quality and quantity metrics of pelvic lymph node metastasis and risk of para-aortic lymph node metastasis in stage IB-IIB cervical cancer.
    J Gynecol Oncol. 2018;29:e10.
    Abstract    



  11. LEE KB, Kim YS, Lee JM
    Oncologic outcomes of adjuvant chemotherapy alone after radical surgery for stage IB-IIA cervical cancer patients.
    J Gynecol Oncol. 2018;29:e5.
    Abstract    

    Abstract available

  12. JIANG W, Xiang L, Pei X, He T, et al
    Mutational analysis of KRAS and its clinical implications in cervical cancer patients.
    J Gynecol Oncol. 2018;29:e4.
    Abstract    

    Abstract available

  13. VASSILAKOS P, Tran PL, Sahli R, Low N, et al
    HPV-negative CIN3 and cervical cancer in Switzerland: any evidence of impact on screening policies?
    Swiss Med Wkly. 2017;147:w14559.
    Abstract    



  14. JANG TK, Shin SJ, Chung H, Kwon SH, et al
    A retrospective comparison of outcome in IB2 and IIA cervical cancer patients treated with primary concurrent chemoradiation versus radical hysterectomy with or without tailored adjuvant therapy.
    Obstet Gynecol Sci. 2017;60:549-557.
    Abstract    

    Abstract available

  15. LI X, Tian R, Gao H, Yang Y, et al
    Identification of a histone family gene signature for predicting the prognosis of cervical cancer patients.
    Sci Rep. 2017;7:16495.
    Abstract    

    Abstract available

  16. CASTLE PE, Kinney WK, Xue X, Cheung LC, et al
    Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study.
    Ann Intern Med. 2017 Nov 28. pii: 2664574. doi: 10.7326/M17-1609.
    Abstract    

    Abstract available

  17. RONCO G, Franceschi S
    Cervical Cancer Screening: The Transformational Role of Routine Human Papillomavirus Testing.
    Ann Intern Med. 2017 Nov 28. pii: 2664378. doi: 10.7326/M17-2872.
    Abstract    



  18. HOOI DJ, Meijer CJLM, Witte BI, Bravio IG, et al
    Supravaginal hysterectomy in Curacao prevalence and impact on screening for cervical cancer.
    Prev Med Rep. 2017;8:238-241.
    Abstract    

    Abstract available

  19. HOELLEN F, Waldmann A, Banz-Jansen C, Holtrich U, et al
    Claudin-1 expression in cervical cancer.
    Mol Clin Oncol. 2017;7:880-884.
    Abstract    

    Abstract available

  20. YANG MC, Chien ST, Yang TF, Lin SY, et al
    Downregulation of nuclear and cytoplasmic Chibby is associated with advanced cervical cancer.
    Oncol Lett. 2017;14:6632-6644.
    Abstract    

    Abstract available

  21. DENG H, Deng Y, Liu F, Chen J, et al
    Stomatin-like protein 2 is overexpressed in cervical cancer and involved in tumor cell apoptosis.
    Oncol Lett. 2017;14:6355-6364.
    Abstract    

    Abstract available

  22. HAVERKOS HW, Haverkos GP, O'Mara M
    Co-carcinogenesis: Human Papillomaviruses, Coal Tar Derivatives, and Squamous Cell Cervical Cancer.
    Front Microbiol. 2017;8:2253.
    Abstract    

    Abstract available

  23. HUSSAIN S
    Comparative efficacy of epigallocatechin-3-gallate against H2O2-induced ROS in cervical cancer biopsies and HeLa cell lines.
    Contemp Oncol (Pozn). 2017;21:209-212.
    Abstract    

    Abstract available

  24. LIU Z, Liang H, Wang X, Yang H, et al
    Comparison of graphical optimization or IPSA for improving brachytheraphy plans associated with inadequate target coverage for cervical cancer.
    Sci Rep. 2017;7:16423.
    Abstract    

    Abstract available

  25. GOTO M, Osada S, Imagawa M, Nishizuka M, et al
    FAD104, a regulator of adipogenesis, is a novel suppressor of TGF-beta-mediated EMT in cervical cancer cells.
    Sci Rep. 2017;7:16365.
    Abstract    

    Abstract available

  26. LI M, Nyabigambo A, Navvuga P, Nuwamanya E, et al
    Acceptability of cervical cancer screening using visual inspection among women attending a childhood immunization clinic in Uganda.
    Papillomavirus Res. 2017;4:17-21.
    Abstract    

    Abstract available

  27. HUANG AJ, Zhao Y, Zou XL, Yan J, et al
    [Study on clinical management of HPV(+)/Pap(-) during cervical cancer screening].
    Zhonghua Fu Chan Ke Za Zhi. 2017;52:745-750.
    Abstract    

    Abstract available

  28. XUE FX, Shen DH
    [Challenges and strategies in cervical cancer screening and management of cervical lesions].
    Zhonghua Fu Chan Ke Za Zhi. 2017;52:730-733.
    Abstract    



  29. ZHANG Z, Wang J, Wang X, Song W, et al
    MicroRNA-21 promotes proliferation, migration, and invasion of cervical cancer through targeting TIMP3.
    Arch Gynecol Obstet. 2017 Nov 24. pii: 10.1007/s00404-017-4598.
    Abstract    

    Abstract available

  30. MA C, Zhang Y, Li R, Mao H, et al
    Risk of parametrial invasion in women with early stage cervical cancer: a meta-analysis.
    Arch Gynecol Obstet. 2017 Nov 24. pii: 10.1007/s00404-017-4597.
    Abstract    

    Abstract available

  31. RUIZ R, Serrano M, Ruiz EF, Mantilla R, et al
    [Clinical-pathological features and survival in young women with cervical cancer: a retrospective analysis from the instituto nacional de enfermedades neoplasicas].
    Rev Peru Med Exp Salud Publica. 2017;34:218-227.
    Abstract    

    Abstract available

  32. YU X, Xia J, Li Y, Cao Y, et al
    Baicalein inhibits cervical cancer progression via downregulating long noncoding RNA BDLNR and its downstream PI3K/Akt pathway.
    Int J Biochem Cell Biol. 2017 Nov 23. pii: S1357-2725(17)30300.
    Abstract    

    Abstract available

  33. FOXX AM, Zhu Y, Mitchel E, Nikpay S, et al
    Cervical Cancer Screening and Follow-Up Procedures in Women Age <21 Years Following New Screening Guidelines.
    J Adolesc Health. 2017 Nov 22. pii: S1054-139X(17)30467.
    Abstract    

    Abstract available

  34. VAN HEERDEN LE, van Wieringen N, Koedooder K, Rasch CRN, et al
    Dose warping uncertainties for the accumulated rectal wall dose in cervical cancer brachytherapy.
    Brachytherapy. 2017 Nov 22. pii: S1538-4721(17)30477.
    Abstract    

    Abstract available

  35. TAVASOLI SM, Kane E, Chiarelli AM, Kupets R, et al
    Women's Behaviors Toward Mammogram and Pap Test: Opportunities to Increase Cervical Cancer Screening Participation Rates among Older Women.
    Womens Health Issues. 2017 Nov 23. pii: S1049-3867(17)30348.
    Abstract    

    Abstract available

  36. ANAMAN-TORGBOR JA, King J, Correa-Velez I
    Barriers and facilitators of cervical cancer screening practices among African immigrant women living in Brisbane, Australia.
    Eur J Oncol Nurs. 2017;31:22-29.
    Abstract    

    Abstract available

  37. SHARMA M, Khan R, Aggarwal M, Sharma A, et al
    Modulatory Effects of Chemoradiation on Angiogenic Factors and Laminin in Cervical Cancer: Link with Treatment Response
    Asian Pac J Cancer Prev. 2017;18:2937-2944.
    Abstract    

    Abstract available

  38. HAN SZ, Liu HX, Yang LQ, Cui LD, et al
    Piperine (PP) enhanced mitomycin-C (MMC) therapy of human cervical cancer through suppressing Bcl-2 signaling pathway via inactivating STAT3/NF-kappaB.
    Biomed Pharmacother. 2017 Nov 20. pii: S0753-3322(17)30825.
    Abstract    

    Abstract available

  39. MAO Q, Luo J, Fang J, Jiang H, et al
    Management of radiation-induced rectovesical fistula in a woman using ileum: A case report and review of the literature.
    Medicine (Baltimore). 2017;96:e8553.
    Abstract    

    Abstract available

  40. CHANDRASEKARAN KS, Sathyanarayanan A, Karunagaran D
    miR-214 activates TP53 but suppresses the expression of RELA, CTNNB1, and STAT3 in human cervical and colorectal cancer cells.
    Cell Biochem Funct. 2017;35:464-471.
    Abstract    

    Abstract available

  41. FIRNHABER C, Swarts A, Goeieman B, Rakhombe N, et al
    Cryotherapy reduces progression of cervical intraepithelial neoplasia grade 1 in South African HIV-infected women: a randomized, controlled trial.
    J Acquir Immune Defic Syndr. 2017 Sep 7. doi: 10.1097/QAI.0000000000001539.
    Abstract    

    Abstract available

  42. MUTOH T, Takatsuki H, Mannoji K, Kawamura K, et al
    Regression of uterine cervical diffuse large B-cell lymphoma transformed from mucosa-associated lymphoid tissue lymphoma subsequent to Chlamydia trachomatis eradication.
    Rinsho Ketsueki. 2017;58:912-916.
    Abstract    

    Abstract available

  43. ZHONG Y, Yang J, Xu WW, Wang Y, et al
    KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition.
    Oncogene. 2017;36:6177-6189.
    Abstract    

    Abstract available

  44. MARTINEZ-CAMPOS C, Bahena-Roman M, Torres-Poveda K, Burguete-Garcia AI, et al
    TLR9 gene polymorphism -1486T/C (rs187084) is associated with uterine cervical neoplasm in Mexican female population.
    J Cancer Res Clin Oncol. 2017;143:2437-2445.
    Abstract    

    Abstract available

  45. GUTIERREZ-FRAGOSO K, Acosta-Mesa HG, Cruz-Ramirez N, Hernandez-Jimenez R, et al
    Optimization of Classification Strategies of Acetowhite Temporal Patterns towards Improving Diagnostic Performance of Colposcopy.
    Comput Math Methods Med. 2017;2017:5989105.
    Abstract    

    Abstract available

  46. LALL M, Kumar P, Choudhary A, Dar L, et al
    Oncogenic human papillomavirus types in a high risk population.
    Indian J Med Microbiol. 2017;35:316.
    Abstract    



  47. BARRETT J
    Gender dysphoria: assessment and management for non-specialists.
    BMJ. 2017;357:j2866.
    Abstract    



  48. SUBA EJ, Zarka MA, Raab SS
    Human papillomavirus screening for low and middle-income countries.
    Prev Med. 2017;100:296.
    Abstract    



  49. SHINNICK JK, Kumar N, Beffa L, Miller K, et al
    Management of Low-Grade Cervical Mullerian Adenosarcoma in a 14-Year-Old Girl.
    J Pediatr Adolesc Gynecol. 2017;30:652-654.
    Abstract    

    Abstract available

  50. SUGIYAMA T, Takeuchi S, Itamochi H
    Surgical management of non-invasive uterine clear cell carcinoma.
    J Gynecol Oncol. 2017;28:e55.
    Abstract    



  51. STEVANOVIC S, Pasetto A, Helman SR, Gartner JJ, et al
    Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer.
    Science. 2017;356:200-205.
    Abstract    

    Abstract available

  52. KUMAGAI K, Tsuda M, Fukushi E, Kawabata J, et al
    Iriomoteolides-9a and 11a: two new odd-numbered macrolides from the marine dinoflagellate Amphidinium species.
    J Nat Med. 2017;71:506-512.
    Abstract    

    Abstract available

  53. STEELE CB, Townsend JS, Courtney-Long EA, Young M, et al
    Prevalence of Cancer Screening Among Adults With Disabilities, United States, 2013.
    Prev Chronic Dis. 2017;14:E09.
    Abstract    

    Abstract available

  54. VAN DER HORST J, Siebers AG, Bulten J, Massuger LF, et al
    Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013.
    Cancer Med. 2017;6:416-423.
    Abstract    

    Abstract available

  55. TROISI R, Hatch EE, Titus L
    The Diethylstilbestrol Legacy: A Powerful Case Against Intervention in Uncomplicated Pregnancy.
    Pediatrics. 2016;138.
    Abstract    



  56. KLING JM, Vegunta S, Al-Badri M, Faubion SS, et al
    Routine pelvic examinations: A descriptive cross-sectional survey of women's attitudes and beliefs after new guidelines.
    Prev Med. 2017;94:60-64.
    Abstract    

    Abstract available

  57. LIM AW, Hollingworth A, Kalwij S, Curran G, et al
    Offering self-sampling to cervical screening non-attenders in primary care.
    J Med Screen. 2017;24:43-49.
    Abstract    

    Abstract available

  58. LU Z, Carneiro G, Bradley AP, Ushizima D, et al
    Evaluation of Three Algorithms for the Segmentation of Overlapping Cervical Cells.
    IEEE J Biomed Health Inform. 2017;21:441-450.
    Abstract    

    Abstract available

  59. COLON-LOPEZ V, Gonzalez D, Velez C, Fernandez-Espada N, et al
    Community-Academic Partnership to Implement a Breast and Cervical Cancer Screening Education Program in Puerto Rico.
    P R Health Sci J. 2017;36:191-197.
    Abstract    

    Abstract available

  60. SHI C, Yang Y, Yu J, Meng F, et al
    The long noncoding RNA LINC00473, a target of microRNA 34a, promotes tumorigenesis by inhibiting ILF2 degradation in cervical cancer.
    Am J Cancer Res. 2017;7:2157-2168.
    Abstract    

    Abstract available

  61. BAYIK TEMEL A, Daghan S, Kaymakci S, Ozturk Donmez R, et al
    Effect of structured training programme on the knowledge and behaviors of breast and cervical cancer screening among the female teachers in Turkey.
    BMC Womens Health. 2017;17:123.
    Abstract    

    Abstract available

  62. GIZAW M, Addissie A, Getachew S, Ayele W, et al
    Cervical cancer patients presentation and survival in the only oncology referral hospital, Ethiopia: a retrospective cohort study.
    Infect Agent Cancer. 2017;12:61.
    Abstract    

    Abstract available

  63. KANG AR, An HT, Ko J, Choi EJ, et al
    Ataxin-1 is involved in tumorigenesis of cervical cancer cells via the EGFR-RAS-MAPK signaling pathway.
    Oncotarget. 2017;8:94606-94618.
    Abstract    

    Abstract available

  64. LEONARDI S, Buttarelli M, De Stefano I, Ferrandina G, et al
    The relevance of prelamin A and RAD51 as molecular biomarkers in cervical cancer.
    Oncotarget. 2017;8:94247-94258.
    Abstract    

    Abstract available

  65. LI J, Khan MA, Wei C, Cheng J, et al
    Thymoquinone Inhibits the Migration and Invasive Characteristics of Cervical Cancer Cells SiHa and CaSki In Vitro by Targeting Epithelial to Mesenchymal Transition Associated Transcription Factors Twist1 and Zeb1.
    Molecules. 2017;22.
    Abstract    

    Abstract available

  66. WANG L, Zhu H
    Long noncoding nuclear paraspeckle assembly transcript 1 acts as prognosis biomarker and increases cell growth and invasion in cervical cancer by sequestering microRNA101.
    Mol Med Rep. 2017 Nov 29. doi: 10.3892/mmr.2017.8186.
    Abstract    

    Abstract available

  67. YANG X, Chen GT, Wang YQ, Xian S, et al
    TLR4 promotes the expression of HIF-1alpha by triggering reactive oxygen species in cervical cancer cells in vitro-implications for therapeutic intervention.
    Mol Med Rep. 2017 Nov 20. doi: 10.3892/mmr.2017.8108.
    Abstract    

    Abstract available

  68. JING Y, Wang Y, Wang X, Song C, et al
    Label-free imaging and spectroscopy for early detection of cervical cancer.
    J Biophotonics. 2017 Dec 5. doi: 10.1002/jbio.201700245.
    Abstract    

    Abstract available

  69. YAVAS G, Yavas C, Inan G
    Locally advanced squamous cell cervical cancer in a patient with septate uterus.
    J Contemp Brachytherapy. 2017;9:487-489.
    Abstract    

    Abstract available

  70. YIP WWL, Wong JSY, Lee VWY, Wong FCS, et al
    Throwing the dart blind-folded: comparison of computed tomography versus magnetic resonance imaging-guided brachytherapy for cervical cancer with regard to dose received by the 'actual' targets and organs at risk.
    J Contemp Brachytherapy. 2017;9:446-452.
    Abstract    

    Abstract available

  71. CHAKRABARTI B, Basu-Roy S, Kar SK, Das S, et al
    Comparison of dose volume parameters evaluated using three forward planning - optimization techniques in cervical cancer brachytherapy involving two applicators.
    J Contemp Brachytherapy. 2017;9:431-445.
    Abstract    

    Abstract available

  72. REES I, Jones D, Chen H, Macleod U, et al
    Interventions to improve the uptake of cervical cancer screening among lower socioeconomic groups: A systematic review.
    Prev Med. 2017 Dec 1. pii: S0091-7435(17)30460.
    Abstract    

    Abstract available

  73. AVILES-JIMENEZ F, Guogin Y, Torres-Poveda K, Madrid-Marina V, et al
    On the Search to Elucidate the Role of the Microbiota in the Genesis of Cancer: The Cases of Gastrointestinal and Cervical Cancer.
    Arch Med Res. 2017 Dec 1. pii: S0188-4409(17)30237.
    Abstract    

    Abstract available

  74. ORNELAS IJ, Ho K, Jackson JC, Moo-Young J, et al
    Results From a Pilot Video Intervention to Increase Cervical Cancer Screening in Refugee Women.
    Health Educ Behav. 2017 Dec 1:1090198117742153. doi: 10.1177/1090198117742153.
    Abstract    

    Abstract available

  75. TAMBUNAN USF, Parikesit AA, Nasution MAF, Hapsari A, et al
    Exposing the Molecular Screening Method of Indonesian Natural Products Derivate as Drug Candidates for Cervical Cancer.
    Iran J Pharm Res. 2017;16:1113-1127.
    Abstract    

    Abstract available

  76. JAIN A, Ganesh B, Bobdey SC, Sathwara JA, et al
    Sociodemographic and Clinical Profile of Cervical Cancer Patients Visiting in a Tertiary Care Hospital in India.
    Indian J Med Paediatr Oncol. 2017;38:291-295.
    Abstract    

    Abstract available

  77. TILBORGHS S, Corthouts J, Verhoeven Y, Arias D, et al
    The role of Nuclear Factor-kappa B signaling in human cervical cancer.
    Crit Rev Oncol Hematol. 2017;120:141-150.
    Abstract    

    Abstract available

  78. BURCHELL AN, Kendall CE, Cheng SY, Lofters A, et al
    Cervical cancer screening uptake among HIV-positive women in Ontario, Canada: A population-based retrospective cohort study.
    Prev Med. 2017 Nov 29. pii: S0091-7435(17)30464.
    Abstract    

    Abstract available

  79. ELIT L, Ogilvie G, Lee M
    Cervical Cancer Screening in Low-Resource Settings.
    J Obstet Gynaecol Can. 2017;39:1183-1184.
    Abstract    



  80. GUO J, Yang Z, Yang X, Li T, et al
    miR-346 functions as a pro-survival factor under ER stress by activating mitophagy.
    Cancer Lett. 2018;413:69-81.
    Abstract    

    Abstract available

  81. HUANG SS, Hao DZ, Zhang Y, Liu HM, et al
    Progress in studies of the mechanisms and clinical diagnosis of cervical carcinoma associated with genomic integration of high-risk human papillomavirus DNA.
    Yi Chuan. 2017;39:775-783.
    Abstract    

    Abstract available

  82. SHISHODIA G, Verma G, Das BC, Bharti AC, et al
    miRNA as viral transcription tuners in HPV-mediated cervical carcinogenesis.
    Front Biosci (Schol Ed). 2018;10:21-47.
    Abstract    

    Abstract available

  83. MUSLIMOVA S
    [THE ROLE OF PAPILLOMAVIRUS INFECTION IN THE DEVELOPMENT OF BACKGROUND DISEASE OF THE CERVIX].
    Georgian Med News. 2017;.
    Abstract    

    Abstract available

  84. CHUCK KW, Hwang M, Choi KS, Suh M, et al
    Cancer screening rate in people with diabetes in the Korean population: results from the Korea National Health and Nutrition Examination Survey 2007-2009.
    Epidemiol Health. 2017;39:e2017036.
    Abstract    

    Abstract available

  85. MOI H

    Tidsskr Nor Laegeforen. 2017;137:700.
    Abstract    



  86. JONAH L, Pefoyo AK, Lee A, Hader J, et al
    Evaluation of the effect of an audit and feedback reporting tool on screening participation: The Primary Care Screening Activity Report (PCSAR).
    Prev Med. 2017;96:135-143.
    Abstract    

    Abstract available

  87. LUXEMBOURG A, Kjaer SK, Nygard M, Ellison MC, et al
    Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine.
    Contemp Clin Trials. 2017;52:54-61.
    Abstract    

    Abstract available

  88. CLENDINEN C, Zhang Y, Warburton RN, Light DW, et al
    Manufacturing costs of HPV vaccines for developing countries.
    Vaccine. 2016 Oct 19. pii: S0264-410X(16)30856.
    Abstract    

    Abstract available

  89. MAYORAL M, Paredes P, Domenech B, Fuste P, et al
    (18)F-FDG PET/CT and sentinel lymph node biopsy in the staging of patients with cervical and endometrial cancer. Role of dual-time-point imaging.
    Rev Esp Med Nucl Imagen Mol. 2017;36:20-26.
    Abstract    

    Abstract available

  90. HENDRICKSON JE, Tormey CA
    Human papilloma virus vaccination and dysautonomia: Considerations for autoantibody evaluation and HLA typing.
    Vaccine. 2016;34:4468.
    Abstract    



  91. KOONMEE S, Bychkov A, Shuangshoti S, Bhummichitra K, et al
    False-Negative Rate of Papanicolaou Testing: A National Survey from the Thai Society of Cytology.
    Acta Cytol. 2017;61:434-440.
    Abstract    

    Abstract available

  92. DE MELO KUIL L, Lorenzi AT, Stein MD, Resende JCP, et al
    The Role of Self-Collection by Vaginal Lavage for the Detection of HPV and High-Grade Intraepithelial Neoplasia.
    Acta Cytol. 2017;61:425-433.
    Abstract    

    Abstract available

  93. TAARNHOJ GA, Christensen IJ, Lajer H, Fuglsang K, et al
    Risk of recurrence, prognosis, and follow-up for Danish women with cervical cancer in 2005-2013: A national cohort study.
    Cancer. 2017 Dec 6. doi: 10.1002/cncr.31165.
    Abstract    

    Abstract available

  94. BENARD VB, Watson M, Saraiya M, Harewood R, et al
    Cervical cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5119-5137.
    Abstract    

    Abstract available

  95. CHEN BJ, Byrne FL, Takenaka K, Modesitt SC, et al
    Transcriptome landscape of long intergenic non-coding RNAs in endometrial cancer.
    Gynecol Oncol. 2017 Oct 16. pii: S0090-8258(17)31367.
    Abstract    

    Abstract available

  96. PHILP L, Covens A, Vicus D, Kupets R, et al
    Feasibility and safety of same-day discharge after laparoscopic radical hysterectomy for cervix cancer.
    Gynecol Oncol. 2017 Sep 28. pii: S0090-8258(17)31350.
    Abstract    

    Abstract available

  97. PEI X, Xiang L, Ye S, He T, et al
    Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix.
    Gynecol Oncol. 2017;147:589-596.
    Abstract    

    Abstract available

  98. DEL CARMEN MG, Rice LW
    International Gynecologic Cancer Society (IGCS) 2016: Meeting report.
    Gynecol Oncol. 2016 Nov 12. pii: S0090-8258(16)31572.
    Abstract    



  99. LIAO JB
    Immunotherapy for Gynecologic Cancers: State of the Science.
    Gynecol Oncol. 2016 May 27. pii: S0090-8258(16)30758.
    Abstract    



  100. VAN DER LINDEN M, Bult P, Nagtegaal ID, Massuger LFAG, et al
    Cervical metastases originating from a primary rectal adenocarcinoma due to a pagetoid spread.
    Hum Pathol. 2017;68:184-188.
    Abstract    

    Abstract available

  101. BASU P, Ponti A, Anttila A, Ronco G, et al
    Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.
    Int J Cancer. 2018;142:44-56.
    Abstract    

    Abstract available

  102. SAND FL, Frederiksen K, Munk C, Jensen SM, et al
    Long-Term Risk of Cervical Cancer Following Conization of Cervical Intraepithelial Neoplasia Grade 3 - A Danish Nationwide Cohort Study.
    Int J Cancer. 2017 Dec 8. doi: 10.1002/ijc.31202.
    Abstract    

    Abstract available

  103. HUCHKO MJ, Ibrahim S, Blat C, Cohen CR, et al
    Cervical cancer screening through human papillomavirus testing in community health campaigns versus health facilities in rural western Kenya.
    Int J Gynaecol Obstet. 2017 Dec 2. doi: 10.1002/ijgo.12415.
    Abstract    

    Abstract available

  104. KIM H, Kim YS, Joo JH, Eom KY, et al
    Tumor Boost Using External Beam Radiation in Cervical Cancer Patients Unable to Receive Intracavitary Brachytherapy: Outcome From a Multicenter Retrospective Study (Korean Radiation Oncology Group 1419).
    Int J Gynecol Cancer. 2017 Nov 17. doi: 10.1097/IGC.0000000000001155.
    Abstract    

    Abstract available

  105. LIU AH, Walker J, Gage JC, Gold MA, et al
    Diagnosis of Cervical Precancers by Endocervical Curettage at Colposcopy of Women With Abnormal Cervical Cytology.
    Obstet Gynecol. 2017;130:1218-1225.
    Abstract    

    Abstract available

  106. FIASCONE S, Vitonis AF, Feldman S
    Topical 5-Fluorouracil for Women With High-Grade Vaginal Intraepithelial Neoplasia.
    Obstet Gynecol. 2017;130:1237-1243.
    Abstract    

    Abstract available

  107. HOU C, Zhuang Z, Deng X, Xu Y, et al
    Knockdown of Trio by CRISPR/Cas9 suppresses migration and invasion of cervical cancer cells.
    Oncol Rep. 2017 Nov 28. doi: 10.3892/or.2017.6117.
    Abstract    

    Abstract available

  108. SMOLIC M, Sombroek C, Bloemers MCWM, van Triest B, et al
    Needle use and dosimetric evaluation in cervical cancer brachytherapy using the Utrecht applicator.
    Radiother Oncol. 2017 Nov 29. pii: S0167-8140(17)32723.
    Abstract    

    Abstract available

  109. HUCHKO MJ, Kahn JG, Smith JS, Hiatt RA, et al
    Study protocol for a cluster-randomized trial to compare human papillomavirus based cervical cancer screening in community-health campaigns versus health facilities in western Kenya.
    BMC Cancer. 2017;17:826.
    Abstract    

    Abstract available

  110. LAI AYT, Perucho JAU, Xu X, Hui ES, et al
    Concordance of FDG PET/CT metabolic tumour volume versus DW-MRI functional tumour volume with T2-weighted anatomical tumour volume in cervical cancer.
    BMC Cancer. 2017;17:825.
    Abstract    

    Abstract available

  111. ANANTHARAJU PG, Reddy DB, Padukudru MA, Chitturi CMK, et al
    Induction of colon and cervical cancer cell death by cinnamic acid derivatives is mediated through the inhibition of Histone Deacetylases (HDAC).
    PLoS One. 2017;12:e0186208.
    Abstract    

    Abstract available

  112. DENIZ S, Kurt B, Oguzoncul AF, Nazlican E, et al
    Knowledge, attitudes and behaviours of women regarding breast and cervical cancer in Malatya, Turkey.
    PLoS One. 2017;12:e0188571.
    Abstract    

    Abstract available

  113. SENAPATI R, Nayak B, Kar SK, Dwibedi B, et al
    HPV genotypes co-infections associated with cervical carcinoma: Special focus on phylogenetically related and non-vaccine targeted genotypes.
    PLoS One. 2017;12:e0187844.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Cervical Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;